Literature DB >> 23023674

Neurodegenerative disease: EPHA4 inhibition rescues neurodegeneration in ALS.

Mariam Faruqi.   

Abstract

Entities:  

Year:  2012        PMID： 23023674     DOI： 10.1038/nrd3853

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans.

Authors:  Annelies Van Hoecke; Lies Schoonaert; Robin Lemmens; Mieke Timmers; Kim A Staats; Angela S Laird; Elke Peeters; Thomas Philips; An Goris; Bénédicte Dubois; Peter M Andersen; Ammar Al-Chalabi; Vincent Thijs; Ann M Turnley; Paul W van Vught; Jan H Veldink; Orla Hardiman; Ludo Van Den Bosch; Paloma Gonzalez-Perez; Philip Van Damme; Robert H Brown; Leonard H van den Berg; Wim Robberecht
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440
  1 in total
  3 in total

Review 1.  Targeting kinase signaling pathways with constrained peptide scaffolds.

Authors:  Laura E Hanold; Melody D Fulton; Eileen J Kennedy
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

Review 2.  Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy.

Authors:  Abbas Mirshafiey; Ghasem Ghalamfarsa; Babak Asghari; Gholamreza Azizi
Journal:  Innov Clin Neurosci       Date:  2014-07

3.  Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis.

Authors:  Karen K Ling; Michaela Jackson; Duah Alkam; Dawei Liu; Norm Allaire; Chao Sun; Mahmoud Kiaei; Alexander McCampbell; Frank Rigo
Journal:  Neurobiol Dis       Date:  2018-03-06       Impact factor: 5.996
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.